[299 Pages Report] The global cell and gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs.



Increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.



The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time.



The pandemic slowed the economic growth of various countries, including the US, Germany, the UK, India, and China. It also resulted in control measures that impacted operations in life science organizations, such as production and research.



Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441



Market Dynamics For Cell and Gene Therapy Manufacturing Services Market are as Follows :


1. DRIVER: Increasing investments in pharmaceutical R&D --

The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies.



2. RESTRAINT: High operational costs associated with cell & gene therapy manufacturing -- Currently, there are 1,200 cell & gene therapies in trials worldwide. There are more than 700 investigational cell & gene therapies in clinical development in the US alone. However, manufacturing facilities have not kept up. It has been estimated that hundreds of facilities will be needed to manufacture the treatments that are now in clinical trials.



3. OPPORTUNITY: Increasing number of cell & gene therapy clinical trials -- In addition to this, according to data released by CGT Catapult, there were 154 ATMP clinical trials ongoing in the UK in 2020 compared to the 127 trials reported in 2019, indicating an increase of more than 20%. This significant growth in the number of cell & gene therapy clinical trials is expected to drive the demand for manufacturing services and, in turn, propel growth in the cell & gene therapy manufacturing services market.




On the basis of type, the cell & gene therapy manufacturing services market is broadly segmented into cell therapy and gene therapy. In 2020, cell therapy accounted for the largest share of the cell & gene therapy manufacturing services market.